Literature DB >> 22168500

Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development.

Jessica Carmen1, Scott R Burger, Michael McCaman, Jon A Rowley.   

Abstract

A major challenge to commercializing cell-based therapies is developing scalable manufacturing processes while maintaining the critical quality parameters (identity, potency, purity, safety) of the final live cell product. Process development activities such as extended passaging and serum reduction/elimination can facilitate the streamlining of cell manufacturing process as long as the biological functions of the product remain intact. Best practices in process development will be dependent on cell characterization; a thorough understanding of the cell-based product. Unique biological properties associated with different types of cell-based products are discussed. Cell characterization may be used as a tool for successful process development activities, which can promote a candidate cell therapy product through clinical development and ultimately to a commercialized product.

Mesh:

Year:  2012        PMID: 22168500     DOI: 10.2217/rme.11.105

Source DB:  PubMed          Journal:  Regen Med        ISSN: 1746-0751            Impact factor:   3.806


  22 in total

1.  CASMI TSCC launch event, Paris, France, July 2013: an assessment of the key barriers to the commercialization and clinical adoption of pluripotent stem cell therapies.

Authors:  Anna French; Kim Bure; David A Brindley
Journal:  Rejuvenation Res       Date:  2014-02       Impact factor: 4.663

2.  The Isolation and Manufacture of GMP-Grade Bone Marrow Stromal Cells from Bone Specimens.

Authors:  Rhayra B Dias; Danielle C Bonfim
Journal:  Methods Mol Biol       Date:  2021

Review 3.  The potential impact of bone tissue engineering in the clinic.

Authors:  Ruchi Mishra; Tyler Bishop; Ian L Valerio; John P Fisher; David Dean
Journal:  Regen Med       Date:  2016-08-23       Impact factor: 3.806

4.  Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use.

Authors:  Patricia Gálvez; Beatriz Clares; Maria Bermejo; Abdelkrim Hmadcha; Bernat Soria
Journal:  Stem Cells Dev       Date:  2014-02-20       Impact factor: 3.272

Review 5.  3D bioprinting of functional tissue models for personalized drug screening and in vitro disease modeling.

Authors:  Xuanyi Ma; Justin Liu; Wei Zhu; Min Tang; Natalie Lawrence; Claire Yu; Maling Gou; Shaochen Chen
Journal:  Adv Drug Deliv Rev       Date:  2018-06-21       Impact factor: 15.470

6.  Expansion, harvest and cryopreservation of human mesenchymal stem cells in a serum-free microcarrier process.

Authors:  Thomas R J Heathman; Veronica A M Glyn; Andrew Picken; Qasim A Rafiq; Karen Coopman; Alvin W Nienow; Bo Kara; Christopher J Hewitt
Journal:  Biotechnol Bioeng       Date:  2015-04-20       Impact factor: 4.530

7.  Culture expansion of adipose derived stromal cells. A closed automated Quantum Cell Expansion System compared with manual flask-based culture.

Authors:  Mandana Haack-Sørensen; Bjarke Follin; Morten Juhl; Sonja K Brorsen; Rebekka H Søndergaard; Jens Kastrup; Annette Ekblond
Journal:  J Transl Med       Date:  2016-11-16       Impact factor: 5.531

8.  An ex vivo human cartilage repair model to evaluate the potency of a cartilage cell transplant.

Authors:  Christoph Bartz; Miriam Meixner; Petra Giesemann; Giulietta Roël; Grit-Carsta Bulwin; Jeske J Smink
Journal:  J Transl Med       Date:  2016-11-15       Impact factor: 5.531

9.  An ultra scale-down methodology to characterize aspects of the response of human cells to processing by membrane separation operations.

Authors:  Maria Fernanda Masri; Kate Lawrence; Ivan Wall; Michael Hoare
Journal:  Biotechnol Bioeng       Date:  2017-02-23       Impact factor: 4.530

10.  CellFinder: a cell data repository.

Authors:  Harald Stachelscheid; Stefanie Seltmann; Fritz Lekschas; Jean-Fred Fontaine; Nancy Mah; Mariana Neves; Miguel A Andrade-Navarro; Ulf Leser; Andreas Kurtz
Journal:  Nucleic Acids Res       Date:  2013-12-03       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.